<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671071</url>
  </required_header>
  <id_info>
    <org_study_id>LACOG 0215/EVA 001</org_study_id>
    <nct_id>NCT02671071</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Patients With Uterine Cervical Cancer in Brazilian Health Institutions - The EVITA I Study</brief_title>
  <official_title>Prospective Evaluation of Patients With Uterine Cervical Cancer in Brazilian Health Institutions - The EVITA I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Latin American Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EVA - Grupo Brasileiro de Tumores Ginecológicos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Latin American Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to describe the socio-demographic, clinical
      pathological, quality of life and treatment characteristics of patients diagnosed with CC in
      Brazil.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to describe the socio-demographic, clinical
      pathological, quality of life and treatment characteristics of patients diagnosed with cervix
      cancer (CC) in Brazil. Other specific objectives are:

        -  To describe socio-demographic characteristics: age at diagnosis, education, family
           income, race, occupation, personal health habits - e.g.oral contraceptive use ever/never
           and duration; smoking never/ever/current/duration , ever drinking), sexual history,
           insurance coverage (private, public), institution (private, public, philanthropic),
           obstetric history, comorbidities, performance status, human papillomavirus vaccination
           or not

        -  To describe the screening for CC: access, type, frequency and results.

        -  To describe clinical pathological characteristics of CC: histology (adeno x squamous x
           adenosquamous x neuroendocrine x other) , International Federation of Gynecology and
           Obstetrics (FIGO) stage, pathological stage, exams for staging, date of diagnosis, site
           of metastasis.

        -  To describe treatment characteristics of CC: date of surgery, type of surgery; date and
           duration of radiotherapy, type of radiotherapy; date, type and lines of systemic therapy
           (chemotherapy, monoclonal antibodies),

        -  To describe treatment safety (grade 3-4 AEs, death due to treatment toxicity,
           discontinuation due to AE). In addition adverse events of special interest will be
           described (details on Safety section).

        -  To describe the outcomes: follow-up exams and date of visits, persistent disease,
           recurrence, progression times in metastatic disease, complications (e.g.
           hydronephrosis/nephrostomy/ GI perforations and both GI &amp; genitourinary fistulae.),
           death due CC and death from any cause.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Characterization of cervix cancer in the Brazilian female population</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Socio-demographic characteristics of the female population diagnosed with CC</measure>
    <time_frame>Month 0 (beginning of the study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the method used to diagnose the brazillian female patients with cervix cancer</measure>
    <time_frame>Month 0</time_frame>
    <description>Screening tests (Papanicolaou test) or symptoms presented by patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The clinical and pathological characteristics of cervix cancer in brazilian female patients</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of treatment assessed in patients with CC</measure>
    <time_frame>Month 0, 3, 6,12, 24 and 36</time_frame>
    <description>Radiotherapy, Chemotherapy and/or Surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with disease survival</measure>
    <time_frame>Month 3, 6, 12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with progression survival</measure>
    <time_frame>Month 3, 6, 12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with overall survival</measure>
    <time_frame>Month 3, 6, 12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with disease overall survival</measure>
    <time_frame>Month 3, 6, 12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type and description of the indicated treatment after the diagnosis of cervix cancer in brazilian female patients</measure>
    <time_frame>Month 0, 3, 6,12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment after the diagnosis of cervix cancer</measure>
    <time_frame>Month 0, 3, 6,12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of adverse effects of the cervix cancer treatment</measure>
    <time_frame>Month 0, 3, 6,12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse effects of the cervix cancer treatment</measure>
    <time_frame>Month 0, 3, 6,12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of clinical outcomes of the patients with cervix cancer in Brazil</measure>
    <time_frame>Month 0, 3, 6,12, 24 and 36</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Cervix Cancer</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Quality of Life Questionnaire (QLQ)</intervention_name>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Cervical cancer module (EORTC QLQ-CX24) will be applied to all patients at 0, 3, 6, 12, 24, 36 months.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with cervical cancer in 1-year period (recently diagnosed IB to IIA high
        risk or IIB-IVB or recurrent disease - FIGO stages) at the participating sites will be
        included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic confirmed invasive cervical cancer

          -  Diagnosis of FIGO stages

          -  Stage 1B to 2A high risk

          -  2B-4B or recurrent disease

          -  Patients ≥18 years old

        Exclusion Criteria:

          1. Non-invasive uterine carcinoma;

          2. Pregnancy;

          3. synchronous tumor or second primary tumor in the past 5 years (except thyreoid ancer
             or non-melanoma skin cancer).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Werutsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Latin American Cooperative Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Voelcker</last_name>
    <phone>55 51 3384 5334</phone>
    <email>laura.voelcker@lacog.org.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raíra Maschmann</last_name>
    <phone>55 51 3384 5334</phone>
    <email>raira.maschmann@lacog.org.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fundação Centro de Controle do Câncer do Estado do Amazonas</name>
      <address>
        <city>Manaus</city>
        <state>Amazonas</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kátia Torres, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Kátia Torres, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica AMO</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabela Almeida</last_name>
    </contact>
    <investigator>
      <last_name>Aknar Calabrich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRIO</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Gomes</last_name>
    </contact>
    <investigator>
      <last_name>Eduardo Cronenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Alderona Bello</name>
      <address>
        <city>Sao Luis</city>
        <state>Maranhão</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Parentes</last_name>
    </contact>
    <investigator>
      <last_name>Rachel Cossetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UFMG</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Marinho</last_name>
    </contact>
    <investigator>
      <last_name>Angélica Rodrigues, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Erasto Gaertner</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taís Bisetto</last_name>
    </contact>
    <investigator>
      <last_name>João Nunes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IMIP</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Menor</last_name>
    </contact>
    <investigator>
      <last_name>Carla Rameri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital São Vicente de Paulo</name>
      <address>
        <city>Passo Fundo</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nincia Kaross</last_name>
    </contact>
    <investigator>
      <last_name>Felipe Thomé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CPO - Hsl/Pucrs</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Webber</last_name>
    </contact>
    <investigator>
      <last_name>Fernanda Damian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Roraima</name>
      <address>
        <city>Boa Vista</city>
        <state>Roraima</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allex Jardim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Allex Jardim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CEPON</name>
      <address>
        <city>Florianopolis</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camila Sommer</last_name>
    </contact>
    <contact_backup>
      <last_name>Camila Donadel</last_name>
    </contact_backup>
    <investigator>
      <last_name>Lizana Arend, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Novos Tratamentos Litoral - Itajaí</name>
      <address>
        <city>Itajaí</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karyn Maman</last_name>
    </contact>
    <investigator>
      <last_name>Giuliano Borges, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INCA</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Baldino</last_name>
    </contact>
    <investigator>
      <last_name>Andréia Melo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital São José</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Lang</last_name>
    </contact>
    <investigator>
      <last_name>Fernando Maluf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Brasileiro de Controle do Câncer - IBCC</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliana Mauri</last_name>
    </contact>
    <investigator>
      <last_name>André Lopes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.</citation>
    <PMID>21296855</PMID>
  </reference>
  <reference>
    <citation>Muñoz N, Franco EL, Herrero R, Andrus JK, de Quadros C, Goldie SJ, Bosch FX. Recommendations for cervical cancer prevention in Latin America and the Caribbean. Vaccine. 2008 Aug 19;26 Suppl 11:L96-L107. doi: 10.1016/j.vaccine.2008.05.062. Review.</citation>
    <PMID>18945407</PMID>
  </reference>
  <reference>
    <citation>Hellner K, Münger K. Human papillomaviruses as therapeutic targets in human cancer. J Clin Oncol. 2011 May 1;29(13):1785-94. doi: 10.1200/JCO.2010.28.2186. Epub 2011 Jan 10.</citation>
    <PMID>21220591</PMID>
  </reference>
  <reference>
    <citation>Martínez-Mesa J, Werutsky G, Campani RB, Wehrmeister FC, Barrios CH. Inequalities in Pap smear screening for cervical cancer in Brazil. Prev Med. 2013 Oct;57(4):366-71. doi: 10.1016/j.ypmed.2013.06.026. Epub 2013 Jul 1.</citation>
    <PMID>23827721</PMID>
  </reference>
  <reference>
    <citation>Zuliani AC, Esteves SC, Teixeira LC, Teixeira JC, de Souza GA, Sarian LO. Concomitant cisplatin plus radiotherapy and high-dose-rate brachytherapy versus radiotherapy alone for stage IIIB epidermoid cervical cancer: a randomized controlled trial. J Clin Oncol. 2014 Feb 20;32(6):542-7. doi: 10.1200/JCO.2013.50.1205. Epub 2014 Jan 21.</citation>
    <PMID>24449243</PMID>
  </reference>
  <reference>
    <citation>Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, MacLean G, Souhami L, Stuart G, Tu D. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002 Feb 15;20(4):966-72.</citation>
    <PMID>11844818</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2016</study_first_submitted>
  <study_first_submitted_qc>January 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervix Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

